Literature DB >> 14767748

The economic burden of supportive care of cancer patients.

Linda S Elting1, Ya-Chen Tina Shih.   

Abstract

GOALS OF WORK: Economic and regulatory healthcare policy is limited by the lack of population-based information on the cost of supportive care of cancer patients. The goal of this study was to estimate these costs and to explore the impact of these costs on policy decisions. PATIENTS AND METHODS: We identified estimates of the cost of outpatient and inpatient supportive care from published reports in the literature. The range of these costs (from lowest to highest) is described for each supportive care condition. These estimates were supplemented by computing the cost of all hospitalizations for these conditions in Texas between June 2000 and December 2001. Medicare payments were used to estimate average reimbursement. Costs (not charges) were standardized to 2002 US dollars using the consumer price index for medical care and Medicare's cost-to-charge ratio for Texas. MAIN
RESULTS: Inpatient care for most conditions exceeded 7,000 US dollars per episode. Our population-based estimates of the cost of care were similar to literature-based estimates, except in the case where conditions could be managed in the outpatient setting. Average Medicare payments were often far lower than the estimated cost of care. For example, the estimated cost of hospitalization for management of diarrhea was 6,616 US dollars while the average Medicare payment was only 2,809 US dollars.
CONCLUSIONS: Many supportive care interventions are quite expensive. In an environment focused on cost containment, a risk-based approach to expensive supportive care treatments is essential. Further study of the cost effectiveness of supportive care management strategies is indicated.

Entities:  

Mesh:

Year:  2004        PMID: 14767748     DOI: 10.1007/s00520-003-0513-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  51 in total

1.  The economic burden of COPD.

Authors:  S D Sullivan; S D Ramsey; T A Lee
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

2.  Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.

Authors:  D J Stewart; S Dahrouge; D Coyle; W K Evans
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

3.  Management paradigms for posterior epistaxis: A comparison of costs and complications.

Authors:  E D Monte; M J Belmont; M K Wax
Journal:  Otolaryngol Head Neck Surg       Date:  1999-07       Impact factor: 3.497

4.  Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.

Authors:  C L Bennett; J A Weeks; M R Somerfield; J Feinglass; T J Smith
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

5.  Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema.

Authors:  L Wilson; E B Devine; K So
Journal:  Respir Med       Date:  2000-03       Impact factor: 3.415

6.  Platelet transfusions: utilization and associated costs in a tertiary care hospital.

Authors:  K R Meehan; C O Matias; S S Rathore; S G Sandler; J Kallich; J LaBrecque; H Erder; K A Schulman
Journal:  Am J Hematol       Date:  2000-08       Impact factor: 10.047

7.  Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.

Authors:  E A Calhoun; C H Chang; E E Welshman; D A Fishman; J R Lurain; C L Bennett
Journal:  Oncologist       Date:  2001

8.  An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada.

Authors:  R A Zabinski; T A Burke; J Johnson; F Lavoie; C Fitzsimon; R Tretiak; J V Chancellor
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

9.  What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis.

Authors:  A Ortega; G Dranitsaris; A L Puodziunas
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

10.  Complications and costs after high-risk surgery: where should we focus quality improvement initiatives?

Authors:  Justin B Dimick; Peter J Pronovost; John A Cowan; Pamela A Lipsett
Journal:  J Am Coll Surg       Date:  2003-05       Impact factor: 6.113

View more
  9 in total

1.  What Oncologists Must Account for: The Financial Burden of Cancer-Associated Symptom Relief.

Authors:  Fantine Giap; Fumiko Chino
Journal:  JCO Oncol Pract       Date:  2021-11-30

2.  Mouthwash Containing Vitamin E, Triamcinolon, and Hyaluronic Acid Compared to Triamcinolone Mouthwash Alone in Patients With Radiotherapy-Induced Oral Mucositis: Randomized Clinical Trial.

Authors:  Farzaneh Agha-Hosseini; Mona Pourpasha; Massoud Amanlou; Mahdieh-Sadat Moosavi
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

3.  Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant.

Authors:  Michael W Schuster; Tsiporah B Shore; John G Harpel; June Greenberg; Bita Jalilizeinali; Scott Possley; Robert W Gerwien; William Hahne; Yuan-Di C Halvorsen
Journal:  Support Care Cancer       Date:  2007-08-21       Impact factor: 3.603

4.  A prospective study to assess in vivo optical coherence tomography imaging for early detection of chemotherapy-induced oral mucositis.

Authors:  Alden Calantog; Lucy Hallajian; Tasneem Nabelsi; Stephanie Mansour; Anh Le; Joel Epstein; Petra Wilder-Smith
Journal:  Lasers Surg Med       Date:  2013-01-15       Impact factor: 4.025

Review 5.  The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue.

Authors:  Alan Carlotto; Virginia L Hogsett; Elyse M Maiorini; Janet G Razulis; Stephen T Sonis
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981

6.  Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue.

Authors:  Claudia Canella; Michael Mikolasek; Matthias Rostock; Matthias Guckenberger; Josef Jenewein; Esther Linka; Claudia Six; Sarah Stoll; Roger Stupp; Claudia M Witt
Journal:  BMC Cancer       Date:  2020-05-24       Impact factor: 4.430

7.  Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective.

Authors:  Yingcheng Wang; Mingjun Rui; Xin Guan; Yingdan Cao; Pingyu Chen
Journal:  Front Med (Lausanne)       Date:  2021-06-02

8.  The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study.

Authors:  Roberto Ippoliti; Greta Falavigna; Federica Grosso; Antonio Maconi; Lorenza Randi; Gianmauro Numico
Journal:  Int J Health Policy Manag       Date:  2018-08-01

9.  Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.

Authors:  Xinglu Xu; Nan Fang; Huanan Li; Yanyan Liu; Fan Yang; Xin Li
Journal:  Ann Transl Med       Date:  2021-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.